Experience with the use of inhaled carbapenems in a Spanish Cystic Fibrosis Unit
M. Bascuas Arribas (Madrid, Spain), P. Fernández García (Madrid, Spain), V. Sanz Santiago (Madrid, Spain), S. Martín Hernández (Madrid, Spain), A. López Neyra (Madrid, Spain), B. Hernández Millán (Madrid, Spain), J. Alvarez-Coca (Madrid, Spain), M. Camino Serrano (Madrid, Spain), F. Romero Ándujar (Madrid, Spain), J. Villa Asensi (Madrid, Spain), R. Girón Moreno (Madrid, Spain)
Source: International Congress 2022 – Cystic fibrosis in children and adolescents
Session: Cystic fibrosis in children and adolescents
Session type: Thematic Poster
Number: 286
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Bascuas Arribas (Madrid, Spain), P. Fernández García (Madrid, Spain), V. Sanz Santiago (Madrid, Spain), S. Martín Hernández (Madrid, Spain), A. López Neyra (Madrid, Spain), B. Hernández Millán (Madrid, Spain), J. Alvarez-Coca (Madrid, Spain), M. Camino Serrano (Madrid, Spain), F. Romero Ándujar (Madrid, Spain), J. Villa Asensi (Madrid, Spain), R. Girón Moreno (Madrid, Spain). Experience with the use of inhaled carbapenems in a Spanish Cystic Fibrosis Unit. 286
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|